生物
多发性硬化
DNA甲基化
染色质
实验性自身免疫性脑脊髓炎
染色质免疫沉淀
免疫学
癌症研究
基因表达
遗传学
基因
发起人
作者
Michael A. Wheeler,Iain C. Clark,Emily Tjon,Zhaorong Li,Stéphanie Zandee,Charles P. Couturier,Brianna R. Watson,Giulia Scalisi,Sarah Alkwai,Veit Rothhammer,Assaf Rotem,John A. Heyman,Shravan Thaploo,Liliana M. Sanmarco,Jiannis Ragoussis,David A. Weitz,Kevin Petrecca,Jeffrey R. Moffitt,Burkhard Becher,Jack P. Antel,Alexandre Prat,Francisco J. Quintana
出处
期刊:Nature
[Springer Nature]
日期:2020-02-12
卷期号:578 (7796): 593-599
被引量:351
标识
DOI:10.1038/s41586-020-1999-0
摘要
Multiple sclerosis is a chronic inflammatory disease of the CNS1. Astrocytes contribute to the pathogenesis of multiple sclerosis2, but little is known about the heterogeneity of astrocytes and its regulation. Here we report the analysis of astrocytes in multiple sclerosis and its preclinical model experimental autoimmune encephalomyelitis (EAE) by single-cell RNA sequencing in combination with cell-specific Ribotag RNA profiling, assay for transposase-accessible chromatin with sequencing (ATAC–seq), chromatin immunoprecipitation with sequencing (ChIP–seq), genome-wide analysis of DNA methylation and in vivo CRISPR–Cas9-based genetic perturbations. We identified astrocytes in EAE and multiple sclerosis that were characterized by decreased expression of NRF2 and increased expression of MAFG, which cooperates with MAT2α to promote DNA methylation and represses antioxidant and anti-inflammatory transcriptional programs. Granulocyte–macrophage colony-stimulating factor (GM-CSF) signalling in astrocytes drives the expression of MAFG and MAT2α and pro-inflammatory transcriptional modules, contributing to CNS pathology in EAE and, potentially, multiple sclerosis. Our results identify candidate therapeutic targets in multiple sclerosis. Single-cell RNA sequencing of cells from humans with multiple sclerosis and mice with a model of the disease identifies a population of disease-promoting astrocytes in which anti-oxidant and anti-inflammatory proteins are suppressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI